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Butyrate is a natural substance present in biological liquids and tissues. The present paper aims to
give an update on the biological role of butyrate in mammals, when it is naturally produced by the
gastrointestinal microbiota or orally ingested as a feed additive. Recent data concerning butyrate
production delivery as well as absorption by the colonocytes are reported. Butyrate cannot
be detected in the peripheral blood, which indicates fast metabolism in the gut wall and/or in the
liver. In physiological conditions, the increase in performance in animals could be explained
by the increased nutrient digestibility, the stimulation of the digestive enzyme secretions,
a modification of intestinal luminal microbiota and an improvement of the epithelial integrity and
defence systems. In the digestive tract, butyrate can act directly (upper gastrointestinal tract or
hindgut) or indirectly (small intestine) on tissue development and repair. Direct trophic effects
have been demonstrated mainly by cell proliferation studies, indicating a faster renewal of
necrotic areas. Indirect actions of butyrate are believed to involve the hormono–neuro–immuno
system. Butyrate has also been implicated in down-regulation of bacteria virulence, both by direct
effects on virulence gene expression and by acting on cell proliferation of the host cells. In animal
production, butyrate is a helpful feed additive, especially when ingested soon after birth, as it
enhances performance and controls gut health disorders caused by bacterial pathogens. Such
effects could be considered for new applications in human nutrition.
Gastrointestinal microbial ecosystem: Feed additives: Biological role of butyrate: Trophic
effects: Hormono–neuro–immuno system: Animal and human nutrition
Introduction
The SCFA constitute a group of molecules that contain from
one to seven carbon atoms and which exist as straight-
or branched-chain compounds. They mainly originate from
the intestinal bacterial fermentation of plant materials such
as celluloses, fibres, starches and sugars for which mammals
lack the necessary enzymes to split these compounds.
Among the SCFA, acetic, propionic and butyric acid are the
predominant forms. Because SCFA are weak acids with a
pK of # 4·8 and the pH of the gastrointestinal (GI) tract
(GIT) fermentation chambers is nearly neutral, 90–99 % of
the SCFA are present in the GIT as anions rather than as free
acids(1). SCFA have several beneficial effects for animals.
As an example, acetic and propionic acids, due to their
physical and chemical properties, are used as acidifiers in
pig diets in order to help overcome problems in the post-
weaning lag period. Moreover, dietary acidification is
known to be beneficial for the performance of fattening
animals(1,2). For ruminants and herbivorous animals, SCFA
constitute the major substrates for energy production.
Evidence also indicates that there is considerable fermenta-
tion in the caecum and colon of both human and non-
herbivorous animals.
Among the SCFA, butyric acid has received particular
attention. It is a natural substance present in the GIT, in milk
as well as in the sweat and faeces of most mammals. Butyric
acid is available as the Na, K, Mg or Ca salt. The advantage
of salts over free acids is that they are generally odourless
Abbreviations: GI, gastrointestinal; GIT, gastrointestinal tract; GLP, glucagon-like peptide; GPR, G protein-coupled receptor; HSP, heat-
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and easier to handle in the feed manufacturing process
owing to their solid and less volatile form. For the purpose
of the present review, the term ‘butyrate’ is used
interchangeably for the acid, the salt and the anion forms.
In the GIT, butyrate is naturally present in high
concentration in the lumen of the large intestine.
It is preferentially taken up by the colonic epithelium
where it is actively metabolised to produce energy(3,4).
Much attention has been devoted to the anticancerous
properties of butyrate in human nutrition despite numerous
papers suggesting its role as a growth factor. The effects of
butyrate, however, depend on the experimental model
(in vivo, invitro), the state of the cells (normal or cancerous)(5),
the degree of inflammation(6) and the doses used(7).
In addition to the recognised effects on intestinal
metabolism, butyrate shows indirect effects that contribute
to the general metabolism of animals. In all tissues butyrate
is a natural component of cellular metabolism. It may also
act as a growth promoter when added to diets at low doses
(0·1–0·5 g/kg)(8).
The purpose of the present paper is to give an overview of
the properties of butyrate either originating from bacterial
intestinal fermentation or added to the rations of animals.
In addition to the recognised effects on intestinal
metabolism, butyrate shows indirect effects that contribute
to the general metabolism of animals.
Production and delivery of butyrate in the gut
Butyrate production patterns in the gut at birth and during
development
In utero, the intestine of the mammalian fetus is sterile.
At the time of delivery, the intestinal microbiota are acquired
by swallowing maternal anal or vaginal organisms(9).
In poultry, hatching through the eggshell has a similar effect.
The effect of the first inoculum may be lifelong, directing
the development of the immune system and the normal
intestinal microbiota. The bacterial composition of the
inoculum received at birth, the structure of the host’s
intestinal epithelium and the diet all affect the density and
composition of the microbiota(10). These microbiota,
particularly in the large intestine, have a fundamental role
in supplying energy to the host through anaerobic
fermentative processes producing SCFA(11). Another source
of SCFA in general and butyrate in particular is the milk.
Butyric acid is a natural component of mammalian milk,
except for human and sows’ milk where only traces can
be found. In cows’ milk butyrate concentration is about
0·16 g/l(12), which seems to be insufficient to cover the
energy needs of the GI epithelium in the newborn calf but it
may be enough to stimulate GI development together with
milk-borne hormones and growth factors such as insulin,
leptin, glucagon-like peptide (GLP)-2, insulin-like growth
factors, epithelial growth factor and many others(13).
Another source of butyrate in suckling neonates is the
hydrolysis of milk lipids by salivary and gastric lipases.
This source of butyrate is difficult to estimate but it may be
utilised in the upper GIT. In newborn rats, very high levels
of butyrate b-oxidation are detected in colonic epithelial
cells. The high oxidation levels may be explained by the fact
that the animal is geared to use luminal substrates (high-fat
milk diet) with maximum efficiency(14). The stools of
normal full-term infants contain less than 100 mM-SCFA(15),
with acetate being the major and butyrate the minor acid
found in the faeces of formula fed-babies, while virtually no
butyrate is found in the faeces of breast-fed infants(16).
In premature infants deficient in intestinal lactase, high
concentrations of SCFA are produced due to carbohydrate
malabsorption, bacterial overgrowth and poor intestinal
motility and can significantly lower the pH of the intestinal
luminal contents. When specific pathogens, such as
Clostridium difficile, proliferate in this environment, they
can cause necrotising enterocolitis(17). In healthy infants,
fermentation is lower than in adults and butyrate production
is established at a slower rate than for acetate and propionate
but, by 2 years, an adult SCFA profile has emerged(18).
Similar SCFA production patterns have been detected in
animals. In broilers aged 1 d, SCFA increased from
undetectable levels to high concentrations in broilers aged
15 d, and then stabilised(19).
Butyrate production in the gut of adult animals
Large bowel fermentation: the main source of available
butyrate. In ruminants, the resident microbiota
components are essential, as they convert the feed
components into nutrients that are readily available for the
animal. In single-stomached animals, less microbial
involvement is needed, as most nutrients in the diet are
directly available to the host. Whilst bacteria affect the
performance of the host by competing for dietary
compounds, they also provide energy to the host through
fermentation. Based on the location of fermentation,
animals can be classified into forestomach fermenters and
hindgut fermenters. Forestomach fermenters such as
ruminants, camels, hippopotamuses and some monkeys
have a fermentation chamber cranial to the acid-secreting
part of the stomach. Rodents, horses, elephants and most
omnivores and carnivores are hindgut and large intestine
and/or caecum fermenters, with the GIT serving as a
chamber for microbial action and SCFA production(1).
Elsden et al. (20), 60 years ago, compared total SCFA
concentration at different sites in the GIT of a number of
herbivorous and omnivorous species and noticed the highest
concentrations in the caecum, and a progressive decline
along the colon. In mice and rats, a higher concentration of
SCFA was reported in the caecum compared with the
colon(21). While in ruminants the highest concentration of
SCFA was found in the rumen, another peak was measured
in the caecum and colon, indicating that even in forestomach
fermenters considerable further digestion occurs in the large
intestine(1). The intestine contains several different bacterial
species. Saccharolytic bacteria, leading to linear SCFA, CO2
and H2, predominate in the proximal colon, while the
majority of proteolytic bacteria, yielding branched SCFA,
CO2, CH4, H2, phenols and amines, are mainly in the
distal colon where fermentable carbohydrates are depleted
on transit(22,23).
Polysaccharides, oligosaccharides and disaccharides
resistant to the action of hydrolytic enzymes in the upper
GIT enter into the caeco-colon. Here, the carbohydrates are
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depolymerised to their constituent sugars by a wide range of
bacterial cell-associated (Fig. 1) and secreted hydrolytic
enzymes such as b-fructosidase, b-galactosidase, xylanase
and other hydrolases, and are then fermented(24). Energy is
gained in the form of ATP by substrate-level phosphory-
lation during oxidative substrate breakdown via the
fermentation process. The transfer of the resulting reducing
equivalents into the metabolic intermediates leads to the
formation of large amounts of reduced endproducts such
as butyrate, which acts as a terminal electron acceptor in an
environment limited in O2. There are two distinct pathways
for the production of intracellular butyrate in bacteria.
In the first pathway butyryl-CoA is converted to butyrate
with the intermediate formation of butyryl phosphate by the
enzymes phosphotransbutyrylase and butyrate kinase(25).
In the second pathway the enzyme butyryl-CoA:acetate
CoA transferase is involved and transfers the CoA moiety
from butyryl-CoA to external acetate, which leads to the
formation of acetyl-CoA and butyrate. The CoA transferase
route is shown to be more dominant in the human butyrate-
producing microbiota(26). In vitro data show that strains
possessing the CoA transferase convert 75 % of the supplied
glucose into lactate when acetate is absent. In the presence
of acetate, mainly butyrate is produced(27).
Substrates used for bacterial fermentation with butyrate as
endproduct. In the large intestine, the ubiquitous nutrient
glucose is only of secondary importance. Enterocytes use
both glutamine and glucose as the favoured metabolic fuels,
while colonocytes preferentially use butyrate(4). The rate
and amount of butyrate produced along the colonic lumen
depends on the microbiota composition, the chemical
composition, the physical form and the amount of substrates
available in the diet. Substrates can be indigestible
or digestible carbohydrates and, additionally, sloughed
cells, mucus and endogenous secretions may also provide
some fermentable substances. Examples of indigestible
carbohydrates are oligosaccharides (for example, raffinose,
oligofructose, inulin) and NSP which can be soluble
(for example, -glucans) or insoluble (for example, cellulose
and hemicellulose). The former are highly fermentable and
hence generate greater quantities of SCFA in the colon while
the latter have a rather low fermentability but increase the
faecal bulking and decrease the colonic transit time.
The most important digestible carbohydrate is starch,
known as resistant starch (RS; D-glucose units connected by
a-1,4/a-1,6 glucosidic bonds) when it has escaped digestion
and/or absorption in the small intestine. RS can be
subdivided into four types: physically trapped starch
(in coarse grains), RS granules naturally rich in amylose
(i.e. raw potato flour), retrograded starch (i.e. cooked
and cooled potato) and chemically modified starch
(i.e. processed foods)(28).
As a result of increasing concentrations of acidic
fermentation products, the luminal pH in the proximal
colon is lower. This pH seems to boost the formation of
butyrate, as mildly acidic pH values allow butyrate-
producing bacteria to compete against Gram-negative
carbohydrate-utilising bacteria such as Bacteroides
spp.(29). An in vitro fermentation study, using faecal
inoculum, showed that the population of butyrate producers,
as well as the concentration of butyrate, was significantly
higher at pH 5·5 while Bacteroidetes dominated as the
fermenter was at pH 6·5. Lowering the pH value further,
for example, to pH 5·2, resulted in the loss of lactate-
utilising bacteria, such as Eubacterium hallii, leading to the
accumulation of lactic acid(29). Although all dietary
fermentable carbohydrates reaching the hindgut have the
potential to be converted to butyrate, not all are equally
butyrogenic. In vitro (30), animal(31) and human(32) studies
have shown that RS fermentation generates relatively more
butyrate than NSP fermentation. Butyrogenic substrates
may affect the fermentative metabolism in individual
bacteria, as more substrate leads to enhanced butyrate
formation, which provides a route for the disposal of excess
reducing equivalents (i.e. butyrate is used as a hydrogen
sink). Butyrogenic substrates may also affect the microbial
population by stimulating butyrate-producing species that
are efficient primary degraders of these substrates(33).
Indirect stimulation of butyrate production occurs by
metabolic cross-feeding. The first mechanism is via cross-
feeding of oligosaccharide breakdown products released by
active polysaccharide-metabolising bacteria. These
breakdown products are then fermented by butyrate
producers. This was demonstrated in in vitro cultures
between bifidobacteria and butyrate-producing species(34).
The second mechanism is via cross-feeding of fermentation
products such as lactate, ethanol and succinate. These
compounds are intermediates in the global fermentation
process in the microbiota and are detected in very low
concentrations in healthy subjects. In vitro, the accumula-
tion of lactate is prevented when human butyrate-producing
strains such as Eubacterium hallii and Anaerostipes caccae
are grown in co-culture with lactate-producing strains such
as Bifidobacterium adolescentis (35).
Scientific reports support the view that RS is the most
powerful butyrogenic substrate(36). Both in vitro as well as
in vivo fermentation of RS generally results in butyrate
production in the order of 20 to 28 mol% compared with
about 10 to 15 mol% for NSP(37). In rats fed RS-containing
diets, there was a significant increase of the number of
bifidobacteria and lactobacilli. Although these bacteria are
Bacterial cell-associated
hydrolytic enzymes
oses - oligosides
Metabolic intermediates
(lactate, succinate, formate, etc)
Polysaccharides
Oligosaccharides
Disaccharides
ButyratePropionateAcetate
H2
Saccharolytic flora
CO2
Fig. 1. Overview of butyrate production in the gut of adult animals.
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predominantly acetate and lactate producers and not
butyrate producers, butyrate production was significantly
enhanced. Therefore it was accepted that the increased
number of lactic acid bacteria induced a higher production
of lactate that was efficiently converted to butyrate by lactic
acid-utilising bacteria(38). Due to the variable structure and
complexity of starch, the exact starch type has a
considerable impact(37). Among RS, the retrograded RS
(RS3) seems to be the most powerful butyrogenic
substrate(37). The butyrogenic properties of RS3 is linked
to the length of the 1,4-a-D-glucans chain. Chain lengths
with a degree of polymerisation of about 20–35 units of
glucose are optimal for a high output of butyrogenic
RS3(39). It is possible to increase the butyrate production
from RS3 fermentation by an appropriate hydrothermal
treatment. In a recent study, Jacobasch et al. (39)
compared the physiological effects of three RS3 in rats:
Novelose 330, annealing-Novelose and heat moisture-
treated Novelose. In the caecum, proximal colon and
distal colon treated with RS3, the digestive concentration
of butyrate significantly increased and in the distal colon,
heat moisture-treated Novelose yielded the highest
butyrate concentration. This result is of great importance
because a high butyrate concentration in the distal part of
the colon is considered to be essential for colonocyte
health and may have many implications in the prevention
and the treatment of some chronic digestive diseases such
as diverticulosis. The ability to produce butyrate from RS
is also a dose-related effect and may vary greatly among
individuals(40).
Oligofructose compounds are also associated with greater
butyrate production. Although oligofructose is thought to be
selectively fermented by bifidobacteria and, to a lesser
extent, by lactobacilli, due to their production of
b-fructosidase that cleaves the b-(2-1) bonds present in
oligofructose and inulin, stimulation of butyrate-producing
bacteria is observed(41).
Besides dietary fibres, other substrates using different
mechanisms are known to increase butyrate concentration.
An example is acarbose, an oligosaccharide that increases
the amount of starch entering the colon by acting as an
a-glucosidase inhibitor(42). Also, the kinetics of butyrate
production varies widely between substrates. For example,
fructo-oligosaccharides are known to be rapidly fermented,
whereas RS is more slowly degraded and can reach the
distal part of the colon(43,44).
There is little information to explain why bacterial
fermentation of specific carbohydrates, such as RS and
oligofructose, selectively increases butyrate production, but
it is assumed that interconversion reactions from primarily
lactate and acetate are largely involved. In the rumen up to
60 % of butyrate is synthesised directly from extracellular
acetate through interconversion reactions(45). Acetate and
butyrate are interconvertible, but due to the net gain of ATP,
the conversion of butyrate to acetate is more favourable for
the microbial metabolism(46).
Butyrate-producing microbiota. Culture-independent sur-
veys of the adult human gut microbiota have revealed two
bacterial phyla, the Bacteroidetes and the Firmicutes(47),
commonly dominating this ecosystem. This is also the
case for the gut of at least sixty mammalian species(48).
The dominant groups found in the large intestines of human
subjects(49), pigs(50) and horses(51) and in the rumen of cattle
are the Cytophaga, Flavobacterium, Bacteroides (CFB)
group of Gram-negative bacteria, and the Clostridium
cluster XIVa (Clostridium coccoides) and cluster IV
(Clostridium leptum) group of Gram-positive bacteria(10).
In poultry, relatives of Clostridium leptum and Clostridium
coccoides groups dominate the caecum(52). A high
frequency of the Sporomusa group (Clostridium cluster
IX), which includes major propionate producers, was
reported while no numbers of the CFB group were
detected in the avian caecum(53). Sonnenburg et al. (54)
demonstrated that members of the Bacteroidetes phylum
harbour a large set of genes which encode functions
necessary to detect, bind, degrade and import carbo-
hydrates encountered in the gut habitat – either from the
diet or from host glycans associated with mucus and the
surfaces of epithelial cells. The substrate breakdown
products released by those primary degraders may be used
by a myriad of other bacterial groups including the
butyrate-producer group. The butyrate-producing bacteria
cultured so far are strictly anaerobic firmicute bacteria,
generally regarded as difficult to grow in vitro. The
bacteria are Gram-positive, having a low mol% guanine-
cytosine (G-C) content and are widely distributed across
several clusters within the order Clostridiales. Those
clostridial clusters (I–XIX) form a new nomenclature that
rearranges the grouping of bacteria based on studies of the
evolutionary relationships by 16S rRNA sequencing(55).
The bulk of the butyrate-producers belong to cluster IV
and cluster XIVa and include some potentially important
butyrate producers related to Faecalibacterium prausnitzii,
Eubacterium rectale and Roseburia species, respec-
tively(56). In humans, the butyrate-producing bacteria
related to F. prausnitzii comprise 5–15 % of the total
microbiota(49) and 5–10 % of the total microbiota species
are related to Eubacterium rectale and Roseburia (57).
In recent studies of poultry, two butyrate producers were
described: Butyricicoccus pullicaecorum(58), related to
F. prausnitzii, and A. butyraticus (59), closely related to
A. caccae, the lactate-utilising bacteria routinely detected
in faecal samples from healthy individuals(10). In the
rumen of cattle and sheep, predominating butyrate-
producing bacteria belong to cluster XIVa and are
represented by Butyrivibrio fibrisolvens strains(60,61).
Butyrivibrio fibrisolvens is also present in the faecal
flora of man, rabbits and horses(62).
Depending on the environmental conditions, fermentative
metabolism of butyrate producers can result in butyrate,
formate, H2, CO2, while lactate and acetate can be either
produced or consumed(56). Butyrate producers are
considered to play an important role in maintaining gut
health mainly through the production of butyrate. Other
traits beneficial for the hosts’ health are their capacity to
stabilise the luminal pH by consumption of lactate or the
anti-inflammatory effect of some butyrate producers(63).
Given the importance of butyrate to colonic epithelial
metabolism, it is reasonable to assume that
butyrate-producing bacteria are well tolerated by the innate
immune system(64).
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Absorption, transport and metabolism of butyrate
Absorption of butyrate, SCFA membrane receptor and
transport proteins
Earlier studies have demonstrated that SCFA are absorbed in
both the small and large intestine by similar mechan-
isms(65,66). More recent studies suggest the existence of
species differences and different transporter isoforms
expressed in enterocytes along the intestine(67). On the
apical membrane of the epithelial cell, distinct transport
mechanisms have been reported, i.e. non-ionic diffusion and
mechanisms involving SCFA/HCO3
2 exchangers, mono-
carboxylate transporter (MCT) type 1(68,69), and Na-coupled
MCT(70) (SMCT or SLC5A8/12). On the basolateral
membrane, a carrier-mediated, HCO3
2-gradient-dependent
anion–butyrate exchange system (Fig. 2) is found(71). The
human intestine constitutes MCT3, MCT4 and MCT5
isoforms (the MCT6 expression was not found), with low
expression of MCT3 in the ileum, and high expression of
MCT4 and MCT5 found predominantly in distal colon(67).
In ruminant species, the SCFA-transporting mechanisms in
the rumen epithelium are highly efficient, and lead to
absorption of nearly all volatile fatty acids. Anion
competition experiments in the washed ovine reticulorumen
segments revealed that SCFA can be transported by
both bicarbonate-dependent and bicarbonate-independent
protein-coupled mechanisms(72). The latter was not coupled
with MCT.
MCT are involved in butyrate transport in pig and human
colonic luminal membrane. Ritzhaupt et al. (68,69) demon-
strated that butyrate uptake is via a pH-activated,
electroneutral anion exchange system. The optimal pH for
the activity of the colonic butyrate transporter seems to be
5·5. Butyrate transport with MCT is saturable, coupled with
Hþ and inhibited by several monocarboxylates such as
acetate, propionate, pyruvate, L-lactate and a-ketobutyrate.
More recently, a second class of MCT was identified(70),
named SMCT. Two proteins have been cloned: SLC5A8 or
SMCT1 and SLC5A12 or SMCT2(73). Conversely to MCT,
SMCT transport mechanism involves Naþ uptake by the
transport cycle and also uses nicotinate and ketone bodies
as substrates. In the colon, Li et al. (17) showed that
SLC5A12 (or SMCT2) functions as a tumour suppressor.
Ganapathy et al.(70) demonstrated that a non-malignant
colon cell line expresses the transporter contrary to
malignant cells. So, exposure of non-malignant cells to
butyrate does not induce apoptosis. However, when
SLC5A12 (SMCT2) is ectopically expressed in malignant
cells and when butyrate is added in the culture medium,
cells undergo massive apoptosis. In the normal colon,
SLC5A8 is claimed to have less importance in butyrate
transport than MCT1(74) but it plays a key function in
intestinal lactate absorption. In humans, SLC5A8 is
considered a tumour suppressor(75). During the transform-
ation of non-malignant cells into malignant ones, expression
of SLC5A8 is silenced perhaps to avoid butyrate inhibition
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Fig. 2. Absorption of n-butyrate (nC4) in the large intestine and subsequent metabolism. Butyrate transport with monocarboxylate transporters
(MCT) is saturable and coupled with Hþ transport. Several receptors for butyrate have been identified and detected in a variety of tissues including
fat tissue, but the highest expression has been found in immune cells. Butyrate prevents obesity and decreases body fat mass in mice, but the
exact mechanism is unknown. After the intestine, butyrate can be metabolised in the liver to produce fatty acids, cholesterol and ketone bodies.
In the peripheral blood, no significant concentration of butyrate is found. Oestr, oestrone sulfate; OAT7, organic anion transporter 7; GPR, orphan
G protein-coupled receptor for SCFA; SMCT, Na-coupled monocarboxylate transporter. Adapted from Gupta et al. (73)
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of histone deacetylase. But in the presence of butyrate,
expression of SLC5A8 is again enhanced and it increases
cell apoptosis(75). Nevertheless, the lack of susceptibility for
colon cancer in SLC5A8 2 /2 mice and the failure to
detect a significant uptake of butyrate by SLC5A8 question
the role of SLC5A8 both in butyrate transport and colon
cancer suppression(76).
Two orphan G protein-coupled receptors (GPR) for
SCFA, GPR41 (or FFA3) and GPR43 (or FFA2) have been
isolated from the intestine(77 – 82). FFA2 mRNA was detected
in a variety of tissues, but the highest expression was found
in immune cells, including polymorphonuclear cells,
suggesting that SCFA might be involved in the activation
of leucocytes. Indeed, recent studies in (FFA2) GPR43-
deficient mice (Gpr432/2) indicated that acetate adminis-
tration may help in resolution of the inflammatory
response(83). FFA3 has an even more widespread expression
pattern than FFA2, including adipose tissues, pancreas,
spleen, lymph nodes, bone marrow and peripheral blood
mononuclear cells(81). Abundant FFA2 and FFA3 expression
was detected in the rat distal ileum and colon, and the
human ascending colon(78,84,85). Expression was limited to
mucosal cells, and absent in enteric neurons and smooth
muscle cells. Immunohistochemical staining with anti-
FFA2 and anti-FFA3 sera showed FFA2 and FFA3
immunoreactivity in enterocytes and enteroendocrine cells
of open type(78,86). The FFA3 immunoreactive enteroendo-
crine cells were less numerous than the FFA2 cells, and
double-immunostaining for FFA2 and FFA3 revealed no
common localisation in one cell. Both the FFA2- and FFA3-
immunoreactive enteroendocrine cells exhibited peptide
YY, but no 5-hydroxytryptamine, expression, supporting the
evidence for stimulation of peptide YY release by SCFA(78).
The FFA2 and FFA3 distribution and physiological role in
the GIT, involving sensing of luminal content, intestinal
motility, secretion and innate immunity, have been recently
reviewed by Karaki & Kuwahara(86).
In healthy rats fed a fibre-free or a RS-enriched diet and
using [1-13C]butyrate intra-caecal perfusion, the flux of
butyrate production was 0·7–1·8mmol/min whereas portal
flux was from 0·2 to 0·4mmol/min and parietal utilisation
from 0·9 to 1·8mmol/min(87). In unfed pigs with an intra-
caecal perfusion of [1-13]C-butyrate, the parietal utilisation
of butyrate varied from 60 to 120mmol/min when the
concentration of perfused [1-13]C-butyrate varied from 0 to
160mmol/min (L Martin, unpublished results).
Energy source for colonocytes
In vitro studies have demonstrated that butyrate
also represents the preferred energy-providing substrate
for the colonic cells(4,88). Colonocytes exhibit a great
capacity to rapidly metabolise butyrate. Through fatty acid
oxidation, butyrate is entirely oxidised into CO2 or used as a
precursor for lipid synthesis(89). In fact, butyrate is able to
increase lipogenesis from acetyl-CoA or ketone bodies
synthesis via the hydroxyl-methyl-glutaryl-CoA path-
way(90). Consequently, the synthesis of many key com-
ponents of the intestinal epithelial tissue depends on
butyrate metabolism (see later).
As butyrate is a key substrate for colonocytes, very small
quantities reach the general circulation or portal vein.
Guilloteau et al. (8) did not observe any changes in plasma
butyrate concentration in the peripheral circulation in
calves. Nevertheless, the concentration of butyrate in the
portal vein may vary according to the diet. Some substrates
such as RS or oligosaccharides lead to substantial increases
in butyrate concentration in the portal vein(91,92). Hepatic
uptake of butyrate is almost total. In the liver, butyrate
metabolism also yields acetyl-CoA as in colonocytes.
In contrast to single-stomached animals, in vivo studies in
steers revealed important butyrate uptake in the rumen as
well as limited capacity to metabolise butyrate in the
ruminal epithelium and liver. In cattle, butyrate absorption is
saturable and if it exceeds the metabolic capacity, it affects
rumen epithelial, hepatic nutrient metabolism and the
nutrient supply of peripheral tissues(93).
Butyrate transport into the peripheral blood circulation:
is there proof for physiological direct effects?
As shown by Kristensen & Harmon(93) in cattle, substantial
amounts of butyrate produced by rumen microbiota may be
absorbed through the ruminal epithelium and induce a
number of effects via the blood circulation. First, included at
a low dose in the diet (0·3 % of DM), butyrate disappears
from the upper GIT (mainly in the stomach). It is thought to
be metabolised in the GIT wall because it is not found in
blood(8,94). Nevertheless, when ingested with the diet,
in specific conditions, butyrate would be measurable in
peripheral blood(95) and seems to be able to act on peripheral
organs (skeletal muscle, brown adipose tissue, liver, etc).
Second, butyrate generated from dietary fibre fermentation
at a high dose in the hindgut lumen (from 3 to 70 mM)(96) is
quickly absorbed in rodents(97) and transported via the
portal vein to the liver. In humans the butyrate concentration
in the portal vein is about 30mM whereas it is 12mM in the
hepatic vein(1). A significant amount of butyrate is detected
in the portal vein but not in the peripheral circulation in pigs
fed a diet enriched with resistant potato starch(98). Similarly,
using rye fibres as a RS source, butyrate concentration
significantly increases in both the portal vein and peripheral
circulation(99). In pigs, the direct perfusion of sodium
butyrate in the caecum induces a dose-related increase
of butyrate in the portal blood (L Martin, unpublished
results). Butyrate, however, is not regularly detected in the
peripheral blood even after a long period of perfusion with a
supra-physiological solution of butyrate in the colonic
lumen (L Martin, unpublished results). Taken together, these
data suggest that butyrate can be absorbed from the gut and
entirely metabolised either in the gut mucosa or in the liver,
which makes a direct effect of butyrate via blood circulation
unlikely. Indeed, Bloemen et al. (100) showed that in human
patients, no intestinally produced butyrate escaped the
splanchnic area due to a highly efficient hepatic uptake.
Butyrate and hepatic metabolism
Only a small fraction of luminal butyrate can reach the liver
via the portal vein. Nevertheless, the effect of butyrate on
hepatic cell has been studied. In the liver, butyrate leads to
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the production of acetyl-CoA that enters into the citric acid
cycle. It has been shown that the production of acetyl-CoA
via the butyryl-CoA synthase pathway consumes 1 ATP/mol
but due to the reoxidation of reduced compounds, the tissue
ATP content is maintained. In an experiment using isolated
perfused liver of rats, Beauvieux et al. (101) observed that,
unexpectedly, butyrate perfusion led to an impairment in
energy metabolism, i.e. a decrease in net ATP content in
comparison with acetate. The authors hypothesised that
butyrate might impair mitochondrial activity inducing an
uncoupling between the respiration chain and ATP
synthesis. So, the effect of butyrate on hepatic metabolism
appears to be close to that of longer-chain fatty acids.
As long-chain fatty acids play a part in the pathogenesis of
insulin resistance, the effect of butyrate should be
considered in specific nutritional conditions (acarbose
treatment, high level of dietary RS, etc)(102).
When ingested, butyrate enhances glycogen synthesis in
the liver at the same rate as glucose(103). The authors
demonstrated a clear effect on both a decrease in glucose
oxidation and an increase in hepatic glycogen storage. They
postulated that such a mechanism could be one of the
molecular bases to explain the effect of dietary fibres on the
prevention of insulin resistance.
Recently a new organic anion transporter (OAT7) was
specifically identified in the liver(104), exhibiting a significant
transport activity for butyrate (Fig. 2). This transporter
mediates the bidirectional transport of oestrone sulfate in
exchange for butyrate. This exchange with oestrone
sulfate might suggest a contribution (direct or indirect) of
butyrate in liver steroid hormone metabolism. More
fundamentally, the narrow substrate selectivity of OAT7
suggests that butyrate might participate in the efficient
translocation of some sulfate conjugates without inter-
ference from the other anionic compounds such as bile salts.
In other words, butyrate may play a role in the efficiency of
liver detoxification pathways.
Effects of butyrate on gastrointestinal epithelial
cell functions
Several studies have indicated that butyrate, besides
providing epithelial cells with energy, markedly increases
epithelial cell proliferation and differentiation, and
improves colonic barrier function(105 – 108). Butyrate
operates as a signal metabolite in the homeostasis of
colonocytes, regulating the balance between proliferation,
differentiation and apoptosis(109) (Fig. 3).
Cell proliferation
Earlier studies suggested that trophic effects on the GI
epithelium are a result of SCFA. Butyrate is considered to
have the strongest effect, that of acetate is weaker, and that
of propionate is the weakest(110). Butyrate ingestion is
known to modify the microstructure of the small and large
intestines in animals and humans(111 – 115).
In enterocytes. In the small intestine, butyrate enhances
proliferation, differentiation and maturation, and reduces
apoptosis of normal enterocytes, mediated through its
influence on gene expression and protein synthesis(116).
In the small intestine, the crypt depth and the villi height
increase largely in butyrate-supplemented weaning
or weaned pigs(94,117). Interestingly, when infused in the
colon, butyrate was shown to exert trophic effect on ileal and
jejunal epithelial cells, presumably indirectly, through
a neurohormonal mechanism(114,115).
More recent molecular studies investigating cell prolifer-
ation, damage, and programmed death (mainly apoptosis)
revealed that butyrate speeds up intestinal mucosa
maturation during the development or repair after
injury(112). Calves supplemented with low doses of sodium
butyrate showed a significantly increased mitotic index in
the upper jejunum but not in the duodenum or ileum as
compared with controls(8). However, changes in the mitotic
index were not reflected in villi length and tunica mucosa
thickness.
In colonocytes. In contrast to the upper intestine, in the
large intestine the trophic effects appeared only at the place
of butyrate administration. In rodents and swine, all studies
showed that the mass of large-bowel tissue is higher
in animals fed a butyrate-producing diet, compared with
controls(118 – 120). An increase in the length of the colon is
repeatedly reported. Increased butyrate concentrations are
associated with morphological changes of the mucosa(121).
The crypt depth is significantly increased in pigs fed a raw
potato starch diet associated with a decrease in the apoptotic
activity. The secretory activity, but not the number, of
epithelial growth factor-secreting goblet cells is nearly
2-fold increased compared with the controls. Simul-
taneously, the activity of two anti-apoptotic-regulating
proteins is increased (Bcl-2; Bak). An overall reduction of
apoptosis was detected without any effects on mitosis.
Therefore, it was concluded that the main butyrate effect,
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Fig. 3. Multiple effects (local) of butyrate in the intestine.
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in non-tumoural cells, is a shift of apoptosis towards the
middle and basal compartments of the crypts. Conversely, in
the absence of butyrate, there is massive apoptosis of
colonocytes(122).
Two plausible mechanisms are used to explain the
increased proliferation index of colonic mucosa in
physiological conditions(123). The first mechanism is that
butyrate is the main energy source for colonocytes and more
energy stimulates cell growth. The second mechanism
involves the stimulation of the release of GI peptides and/or
growth factors by butyrate acting on cell proliferation.
Apoptosis
In normal cells, butyrate acts as a survival factor but it is an
inducer of apoptosis in human colonic carcinoma cells(122).
In an in vivo study in pigs, inulin-coated butyrate led to a
reduction of apoptosis in the ileal mucosa and an increase in
the length of ileal villi although it had no effect on cell
mitosis(118). Bailo´n et al. (124) evaluated the effects of
butyrate on the proliferation and activation state of different
cell types involved in inflammatory bowel disease: intestinal
epithelial cells, macrophages and T-lymphocytes, using
primary non-transformed cultures and established cell lines.
Low concentrations of butyrate inhibited the proliferation
of all immune cell types, whereas it induced apoptosis only
in activated T-lymphocytes, non-differentiated epithelial
cells and macrophage cell lines, but not in differentiated
epithelial cells or primary macrophages. The induction of
apoptosis was mediated by caspase-3/7 activation
(mitochondrial pathway). Butyrate was only able to modify
cell activation, measured as expression of inflammatory
cytokines, in those cell types in which apoptosis was
induced.
Apoptosis is an important regulatory process against
cancer but various mechanisms can lead cells into a pro-
apoptotic state. Zeng & Briske-Anderson(125) showed that
prolonged butyrate treatment in vitro (HT1080 cells)
increased the expression of both pro-metastatic and anti-
metastatic genes but the net effect was an inhibition of
pro-metastatic and an activation of anti-metastatic genes.
Butyrate also arrested cell growth and migration and
invasion of HT1080 cells by inhibiting histone deacetylases,
and also by acting on non-histone proteins(126) at the first
stages of DNA damage. Once DNA is damaged, butyrate
seems to be ineffective. The absolute concentration of
butyrate is also very relevant, as low amounts of butyrate
enhance cell proliferation while high amounts inhibit it.
In the human colon cancer RKO cell line, butyrate
induced apoptosis through a mechanism involving the
c-Jun-N-terminal kinase (JNK) mitogen-activated protein
kinase (MAPK) kinase pathway(127). In contrast, in
neutrophils obtained from healthy human volunteers,
butyrate increased apoptosis irrespective of their activation
state, by factors other than MAPK and GPR, and their
mechanisms probably relate to their histone deacetylase
inhibition activity, which may control a1 mRNA
expression(128).
In the large intestine, cell proliferation, differentiation
and positional localisation along the crypt axis are
governed by several signalling pathways including the
Wnt/b-catenin pathway(129). When Wnt signalling is
activated, normal cell differentiation and proliferation are
modified, leading to probable cancer genesis(129). Further-
more, the relative levels of Wnt signalling determine
whether cells proliferate or go to apoptosis(126), since
several in vivo studies support the evidence that increased
activation of Wnt transcriptional activity enhances apoptosis
in some cancerous cells. In vitro studies showed that
butyrate hyper-induced Wnt transcriptional activity in some
tumour cell lines(130). The authors conclude that both
relatively high and relatively low level of canonical Wnt
transcriptional activity can lead to cancerous cell apoptosis,
and that cells involved in the tumorigenic process due to
Wnt signalling are more vulnerable to butyrate action.
Beneficial effects on performance and intestinal health
Studies with oral administration of butyrate showed that
butyrate can improve growth performance in production
animals. The effective doses of sodium butyrate were fixed
between 1 and 4 % of DM intake, and protection of the
molecule by microencapsulation in lipid matrix improved
its efficiency. Moreover, slow release of butyrate from a lipid
matrix prevented its rapid metabolism in the stomach and
upper small intestine, thereby increasing the area under the
influence of the molecule(131,132). Butyrate was found to
have widespread positive effects on growth, digestibility and
feed efficiency through the modulation of cell proliferation,
differentiation and function in the GIT, especially mucosal
epithelial cells, and on defence systems (barrier function,
antimicrobial potency, immune system) in healthy and sick
animals(2,94,133 – 138).
Effects on growth performance and digestive efficiency.
Dietary supplementation with butyrate enhanced growth rate
and improved the feed conversion rate in calves before and
during weaning(8,131,139) and in piglets(2,140 – 143). Studies in
neonatal(112) and in weaned(111,138) piglets showed that the
ingestion of butyrate resulted in improved performance,
which was further improved if butyrate was fed sooner rather
than later post-birth. Butyrate supplementation during the
suckling period had no influence on ileal apparent
digestibility, but it significantly improved the faecal apparent
digestibility of feed components after weaning(111). In these
studies, butyrate supplementation delayed gastric emptying,
which may suggest that increased gastric retention (longer-
lasting gastric phase of digestion, slower digesta flow to the
intestine) is beneficial for digestive processes(144,145). In the
newborn calves, the effect of butyrate supplementation both
to the milk replacer and starter diet reduced diarrhoea, and
led to an improved health status in the first weeks of life(131).
In calves fed milk formula based on soyabean protein,
butyrate supplementation improved the DM digestibility and
the digestibility of major components of the diet(146).
Moreover, the concomitant addition of butyrate to milk
replacer and starter mixture may stimulate rumen develop-
ment. Thus, the weight of the rumen (percentage of the whole
stomach) was increased at the expense of the abomasum, and
the ruminal papillae length and width were increased(131),
improving the absorptive surface of the rumen.
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The pancreas weight and the pancreatic protein content
were not modified by butyrate supplementation (3 g/kg DM)
in neonatal pigs and calves(8,112). In contrast, the mitotic
index increased and apoptotic index decreased in exocrine
pancreatic cells in calves(147). These results suggest that
pancreatic growth was not modified by butyrate supplemen-
tation; rather, the pancreatic cell turnover was accelerated.
This corroborates with earlier studies demonstrating pro-
mitotic effects of butyrate in the healthy gut of weaned pigs
in vivo, though without effects on villous – crypt
architecture(142) and supports the suggestion that animals
should receive butyrate supplementation after birth as soon
as possible. Preliminary studies by Pietrzak et al. (148)
demonstrated that butyrate supplementation exerted a pro-
mitotic and anti-apoptotic effect in the small-intestinal
mucosa in calves. This in turn elevated the mitotic:apoptotic
ratio in butyrate-treated calves and resulted in increased villi
height and intestinal absorptive surface.
Taking into account all of these results, butyrate may be
considered as an important factor controlling early postnatal
development of the GIT(135) and it seems that the digestive
process in the intestinal lumen could be more efficient in
animals fed a butyrate-supplemented diet.
Effects on digestive secretions. In piglets, pre-weaning
supplementation of butyrate was found to increase the
densities of gastric parietal cells(138), suggesting an increase
in gastric acid secretion. Indeed, the effects of butyrate had
little association with the enhanced acidity of the ingesta, as
suggested by Manzanilla et al. (94). Intra-ileal administration
of butyrate in pigs caused an acute increase of trypsin and
protein outputs(149). Duodenal butyrate infusion, however,
did not change the mean flow rate of juice and proteins for
1 h after initiating administration, in contrast to observations
after oral supplementation. Moreover, in contrast to
ingestion, butyrate infusion decreased the mean flow rate
of chymotrypsin(146).
In calves, butyrate supplementation in milk formula
increased total daily pancreatic secretions. For pancreatic
juice, this increase was most important from 12 to 17 h after
the morning meal(146). In the same experiment, it was shown
that during the 3 h postprandial period, oral butyrate
supplementation led to a physiological postprandial
decrease of pancreatic secretion. Likewise, butyrate
supplementation was accompanied by a 50 % increase in
activity of elastase II in pancreatic tissue(8). These effects
may be relevant for overall digestive processes, because
during the postprandial 2–3 h the arrival of gastric digesta in
the duodenal lumen is the highest(150,151). These
observations help to explain, at least in part, the increase
of nutrient digestibility by butyrate supplementation.
This hypothesis is supported by the fact that lipase is the
pancreatic component that was the most affected, in parallel
with fat digestibility(146).
In calves and pigs, the activities of brush-border
dipeptidylpeptidase IV, lactase and maltase in the
mid-jejunum and aminopeptidases A and N in the distal
jejunum were increased(8,141). Similar results were reported
in other species (i.e. mouse, rat, guinea-pig, vole, pig, sheep
and goat) when butyrate was used in in vitro preparations,
as an additive in the diet as well as after intravenous
(in conscious or anaesthetised animals) or intraduodenal
administration. Although it is realised that the response can
vary between species(141,152 – 157), the data as a whole
suggest that butyrate in mammalian species acts directly at
the GIT level rather than after its absorption. After oral
administration of physiological doses of butyrate,
butyrate could act directly on the GIT secretions in the
stomach and proximal duodenum but indirectly in the lower
small intestine.
Effects on the defence system. In the GIT, the digestive
defence system includes the mucous layer in the gut
(physical barrier), the innate and adaptative immune
systems and the expression of heat-shock proteins (HSP).
Butyrate has been found to have a profound impact on
the immune system of human subjects and rodents(158)
and to exert anti-inflammatory properties in vivo and
in vitro (159 – 161). Surprisingly, butyrate supplementation
reduced the small intestine mucosal mass(111). This would
suggest that butyrate can interfere with intestinal protein
metabolism(162,163), following a reduced bacterial load and
possibly a lower inflammation locally.
Butyrate administration into the lumen of isolated
vascularly perfused rat colon (5 mM) enhanced mucin
secretion, but increasing the concentration up to 100 mM
provoked a gradual decrease in mucus discharge(164).
In piglets fed a butyrate-supplemented diet, the number
of colonic goblet cells was significantly increased(94). In
milk-fed calves, butyrate enhanced HSP27 and HSP70
expression in the abomasum and in the colon, but not in the
small intestine(8). Perhaps the heat-shock response was
induced indirectly through increasing the numbers of
microbials in GI segments (prebiotic activity of butyrate).
This finding suggests that butyrate used at low doses may
have cytoprotective effects.
Effects on digesta composition (microbiota). There are
few publications studying the effects of inclusion of butyrate
at a low dose in diets for animal and human species on
intestinal microbiota. The relationship between lactobacilli
and enterobacteria populations has traditionally been
considered as an index of desirable or undesirable bacteria
in pigs, relating a high index with a greater resistance to
intestinal disorders(165). Adding butyrate to diets promoted
greater mean values in this ratio(166). Galfi & Bokori(140)
observed changes in the ileal microbiota with a decrease in
the proportion of coliform bacteria and a simultaneous
increase of lactobacilli. Van Immerseel et al. (167), using
microencapsulated butyrate in young chickens, also
demonstrated a decrease in the caecum colonisation of
Salmonella after an experimental infection. It was reported
that oral butyrate supplementation would not influence the
number of total bacteria inhabiting different sections of
the GIT but rather promote the largest changes in the
composition of the jejunal microbiota and in the ecological
structure and metabolic activity of the microbial ecosystem
of the large intestine(166). These authors suggested that such
changes in the upper GIT could potentially modify
the fermentable material reaching the large intestine and,
therefore, modify the microbial activity at the faecal level.
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Protecting effect against inflammatory intestinal diseases
In humans, effects of lower butyrate concentrations have been
reported in patients with ulcerative colitis compared with
healthy subjects and there is evidence to suggest that the
metabolism of butyrate is impaired in ulcerative colitis(168).
In experimental colitis, colonocyte oxidation of butyrate
is markedly suppressed(169), leading to reduced cellular ATP
levels and decreased cell metabolism. Many studies have
demonstrated that delivery of butyrate through local enema or
diet results in a protective or therapeutic effect against
inflammatory bowel diseases(170,171). The role of butyrate in
colitis, however, remains complex. Butyrate exerts trophic
effects on the colonic epithelium and is able to modify the
inflammatory response by inhibiting, for instance, NFkB
activation and HSP expression. In dextran sulfate sodium-
treated rats, it has been shown that butyrate is efficient in
reducing inflammation and in restoring intestinal per-
meability. The mechanisms of action are numerous and,
among them, the inhibition of HSP70 synthesis has been
indicated(161). As mentioned earlier, the effects of butyrate
could be different in normal and cancerous cells, such as for
apoptosis. In HT-29 cell lines, butyrate seems to be able to
prevent inflammation by reducing both cellular permeability
in the colon through PPARg activation and the expression of
IL-8 genes(172). Nevertheless, mechanisms for butyrate action
are not always well known. Butyrate can affect several
components of the colonic barrier, leading to an improvement
in epithelial colonic defence mechanism: mucin (MUC)
production, improvement of intestinal epithelial permeability
and modulation of pro-inflammatory cytokines via impair-
ment in NFkB activation. In vitro, butyrate increases
expression of the MUC gene(173) but the effect seems to be
dose dependent(164). In Caco-2 cells, a decrease in butyrate
increases intestinal permeability(174) and butyrate up-regulates
lipoxygenase 5-LOX, 12-LOX and 15-LOX mRNA
expression(175). The authors suggested that LOX activated
by butyrate may induce cellular differentiation and in addition
it could control tight-junction permeability. A recent paper
showed that one possible mechanism of action of butyrate on
tight junctions involves the AMP-activated protein kinase, but
how this kinase is activated by butyrate remains unclear(174).
One hypothesis could be that butyrate enhances the energetic
state of the cell (increase of cellular ATP content).
In animals and in humans, dietary fibre and SCFA are
stimulators of both GLP-1 and GLP-2 synthesis. Butyrate
appears to be the strongest stimulator of GLP-2(176). There is
already a great number of GLP-2 effects recognised in the
intestine: suppression of gastric acid secretion, decrease in gastric
motility, enhancement of intestinal nutrient transport, increase in
intestinal blood flow, increase in intestinal cell proliferation,
enhancement of intestinal barrier function and inhibition of crypt
cell apoptosis. Recently, GLP2 has emerged as a possible
treatment option against intestinal bowel diseases(177).
Mechanisms of action of butyrate in physiological
and pathological conditions
In physiological conditions
Action on regulatory peptides. Following ingestion of a
butyrate- or butyrate precursor-enriched diet, a common
effect of butyrate on the architecture of the GIT wall can be
found since it stimulates proliferation, differentiation and
maturation, and reduces apoptosis in the cells. The effects
on the forestomach, stomach and hindgut seem to be
direct(131,178), whereas the effects on the pancreas and small
intestine are probably indirect. It is increasingly recognised
that intestinal development (growth and maturation) and
digestive functions depend on a unique neuro-hormonal
and immune-regulatory system mediated by a multitude of
regulatory substances(179). Thus, it has been suggested that
the possible effect of butyrate on GIT development is by its
effects on bioactive peptides or hormones secreted into the
blood and/or locally produced in the GIT(8,146) (J Flaga,
unpublished results). Two candidate regulatory peptides are
gastrin and cholecystokinin, known for their trophic effects
in the upper gut. Cholecystokinin and secretin are also
known to control the secretion of pancreatic juice and bile.
However, no change in the plasma concentration of gastrin,
cholecystokinin and secretin or in the expression of
cholecystokinin or gastrin receptors was observed in calves
fed with a butyrate-enriched diet. These results are in
contrast to an enhanced efficiency of duodenal digestive
functions and suggest that these peptides do not mediate the
butyrate effects(8,146). These findings disagree with data
obtained from in vitro cell-culture studies showing
increased gastrin mRNA expression and gastrin secretion
during butyrate treatment(180). Inhibition of postprandial
circulating somatostatin in calves(8) may be explained by a
direct effect of butyrate on somatostatin-secretin cells.
Plasma pancreatic polypeptide, which inhibits pancreas and
gut secretions, was reduced in newborn piglets following the
ingestion of a butyrate-supplemented milk replacer(112).
The effects of butyrate on the upper small intestine could
involve the GLP-2 pathway in piglets(113) and in calves(131)
in agreement with the fact that GLP-2 is considered an
important endocrine signal activating intestinal adaptation,
cell survival and proliferation in newborn mammals(181,182).
Also, an increase in plasma enteroglucagon levels was
correlated with the increase in the villus height and crypt
depth in the small intestine(159). Finally, there was an
increase in the expression of insulin-like growth factor-1
receptors in the jejunum of butyrate-supplemented calves(8).
These results suggest that part of the effects of butyrate is
likely to be mediated by insulin-like growth factor-1(183).
Patients fed dietary fibre have modified acute postprandial
responses for glucose, insulin and gut hormones(184). Among
gut hormones, GLP-1 stimulates insulin secretion, reduces
the rate of gastric emptying, increases insulin sensitivity and
decreases energy intake(185). As butyrate is able to increase
ileal and colonic proglucagon mRNA expression and
postprandial GLP-1 concentrations in rats, it probably
contributes indirectly via GLP-1 to glucose and energy
metabolism.
Action on the defence system. Butyrate decreases in vitro
lymphocyte proliferation in mice(186) and in rats(187).
In T helper 1 cells butyrate acts as a cell anergy factor.
When activated, T helper 1 cells enter into the G1 phase of
the cell cycle. However, when antigen-presenting cells are
in the presence of butyrate, T helper 1 cell proliferation is
blocked(188). In this case, butyrate requires T-cell receptor
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ligation and Ca mobilisation(188). Moreover, butyrate
increases the secretion of IL-10(189,190), and decreases the
secretion of interferon-g(189) by activated human
lymphocytes in vitro. Butyrate also decreases the ex vivo
production of inflammatory cytokines in intestinal biopsies
of humans suffering from Crohn’s disease, and reduces the
severity of 2,4,6-trinitrobenzenesulfonic acid-induced
colitis in rats(160). Butyrate decreases intestinal expression
levels of TNFa, IL-1b and IL-6 in patients with Crohn’s
diseases(158). In piglets aged 40 d, Le Gall et al. (111) have
observed a tendency to a reduced expression of IL-8, in
agreement with the results of Gibson & Rosella(191) who
have demonstrated that, in vitro, IL-8 secretion by colonic
crypt cells is suppressed by butyrate.
Members of the HSP family have been implicated in an
ever-growing number of cellular activities including the
effects of microbial agents(192). It is reasonable to think that
butyrate may affect (1) microbial composition in the
intestinal lumen and bacterial number (probiotic effect) and
this action may influence HSP expression in the gut tissues,
and (2) the HSP expression in the gut mucosa by itself.
Thus, cell protection is possibly enhanced because of
chaperone activity, mostly ascribed to HSP70 family
members(193). It was shown that HSP25/27 need SCFA for
basal expression in epithelial cells of the colon and in the
distal small intestine in vivo in the rat(194,195), which is in
agreement with the results obtained in the calf(8). In vitro,
SCFA enhance the expression of HSP25/27 in a dose- and
time-dependent manner, an effect that is transcriptionally
regulated(196), and protect rat intestinal epithelial cells from
injury(194). The HSP response is a universal response to cell
injury(197) that could be associated with a stress response of
the GIT epithelium.
In pathological conditions
Butyrate can hardly escape the splanchnic area; it seems
able to act as a systemic mediator in several conditions
(Fig. 4).
Obesity and diabetes. In obese mice fed a high-fat diet,
addition of butyrate to the diet (5 % of the meal) reduced
insulin resistance and increased energy expenditure(95).
In the treated group, butyrate prevented obesity because
there was no increase in fat mass after 16 weeks of treatment
on the high-fat diet. Butyrate increased thermogenic
function in the mice, and treated mice had smaller brown
adipocytes than their control counterparts. The expression
of two thermogenesis-related genes (PPARg coactivator-1a
(PGC-1a) and uncoupling protein-1 (UCP-1)) was
increased in the butyrate group. Fasting insulin was also
50 % lower in the butyrate group, and treated mice showed
much better response to insulin during the intraperitoneal
insulin tolerance test. In addition, butyrate administration
through food supplementation was effective in treating
obesity in dietary obese mice. In agreement with
these results, several studies showed that rats fed RS
(a ‘butyrogenic’ dietary fibre) have lower body fat than their
control counterparts. Moreover, dietary RS up-regulated
hypothalamic pro-opiomelanocortin (POMC) expression
in rats(198). Thus, one mechanism of decreased body fat
is probably linked to POMC expression.
Several neuroendocrine factors are involved in the
regulation of food intake. Among them, peptide YY,
GLP-1 and leptin have been widely studied. Moreover, both
GLP-1 and leptin are implicated in the pathogenesis of
obesity and diabetes. Butyrate directly increases peptide
YY/proglucagon gene expression in vitro (199). Such a result
is observed in vivo in RS-fed rats. Such findings may lead to
the hypothesis that butyrate could also act as a pathogenic
factor in some diseases by increasing food intake. Leptin is
thought to be a sensor of energy stores in the body via the
body fat mass. Numerous data demonstrate that leptin is a
probable humoral link between metabolism and several
neuroendocrine systems. In vitro, butyrate down-regulates
leptin expression in rat anterior pituitary cells(200). In fact,
in vitro, butyrate seems to be able to regulate the synthesis
of some pituitary hormones. Nevertheless, to date these
effects of butyrate have not been confirmed in in vivo
studies and there is also apparent conflict between the
results of clinical studies and animal performance studies. In
clinical trials (inflammatory bowel disease, Crohn’s disease,
ulcerative colitis, etc) it was shown that the body weight of
patients treated with butyrate increased. It was confirmed in
patients with Crohn’s disease who received microencapsu-
lated butyrate (R Zabielski, unpublished results). Concerning
animal production, body-weight gain increases following
butyrate treatment. The appetite is probably increased
and the intestinal microstructure could be improved. Thus,
it is possible that in ‘healthy overweight’ individuals the
response to butyrate may be different from that in patients
with inflammatory bowel disease.
Protection against oxidative damage. Inflammatory
bowel diseases are characterised by recurrent chronic
Direct effects
Indirect effects?
Regulation of gene
expression (effective on
more than 100 genes)
Immune function
stimulation
↑ GLP-1
↑ Proglucagon mRNA
↑ Feed conversion rate
↑ Growth performance
↑ Pancreatic secretions
(lipase +++)
Increase of body
thermogenesis
Control of body adiposity
(through POMC expression?)
Liver detoxification
pathways
Fig. 4. Overview of the multiple effects of butyrate as a systemic
factor. GLP, glucagon-like peptide; POMC, pro-opiomelanocortin.
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inflammation. The inflammatory cells produce large
quantities of reactive oxygen species in the deep layers of
the bowel wall that pave the way for colorectal cancer(201).
Butyrate could modulate the level of oxidative stress both
in vitro and in vivo. In isolated human colonocytes and
in HT29 tumour cells, butyrate shows a protective effect
against oxidative DNA damage induced by H2O2
( 202).
In healthy colon cells, butyrate modulates the expression of
genes associated with oxidative stress(203). In humans, the
expression of human catalase, human cyclo-oxygenase 2 and
human metallothionein 2A is enhanced, whereas that of
glutathione reductase, PG-endoperoxide synthase 2 and
superoxide dismutase 2 is lowered. The authors concluded
that changes could reduce oxidant-damaging effects
and protect cells from cancerogenesis.
Nevertheless, the response to butyrate treatment showed
large variability among donors. Rectal administration
of butyrate enhances the colonic antioxidant capacity of
healthy patients(204). The rectal infusion clearly increases
total glutathione production in perfused biopsies. The
expression of several genes is also modified: increase
of glutathione peroxidase 1, glutathione peroxidase 3 and
glutamate-cysteine ligase catalytic sub-unit, and decrease of
glutathione peroxidase 2, glutathione reductase, glutathione
synthetase and xanthine dehydrogenase. Notably, the effects
of butyrate are not long lasting and disappeared soon after
finishing the infusions.
Mechanism of pathogen control against bacteria. Acetate,
propionate and butyrate are weak acids with pKa values of
approximately 4·8. They have bacteriostatic and bactericidal
properties depending on the physiological status of the
bacteria and the physico-chemical characteristics
of the external environment(205). The concentration of the
undissociated form, which can diffuse freely across the
bacterial lipid membrane into the bacterial cell, is affected
by pH. Therefore pH is a key determinant of effec-
tiveness(206). A pH , 4·8 increases the availability of the
undissociated acid that once internalised into the more
alkaline cytoplasm, dissociates into anions and protons,
thereby reducing the internal pH(207). But bacteria need to
maintain a near-neutral pH in their cytoplasm to sustain
functional macromolecules. Exporting the excess of protons
requires cellular ATP and may result in depletion of cellular
energy leading to cellular damage and/or death. The
accumulation of anions would be the primary toxic effect of
organic acids(206). Some organisms allow a decline of their
internal pH and are therefore more resistant to organic acids
than others. Also inherent resistance via exclusion of the
antimicrobial chemical, secretion of the toxic compound or
metabolic detoxification can influence the efficacy of the
organic acids(206). SCFA are proposed to interfere with
cytoplasmic membrane structures and membrane proteins,
uncoupling electron transport and therefore reducing ATP
production. This interference can also lead to damage in the
cytoplasmic membrane, resulting in leakage or disruption of
outer membrane permeability. Less direct antibacterial
action is the influence of organic acids on macromolecular
synthesis or nutrient transport(206,208).
SCFA are used in pathogen control in the field, especially
against Salmonella in poultry and pigs. In chickens, during
the early stages of life the multiplication of Salmonella is
difficult to prevent by endogenously produced SCFA. As it
is of great importance to prevent initial colonisation of
Salmonella, and because food is a major source for
Salmonella introduction to the farm, drinking water and
food are commonly acidified. By creating a barrier at the
level of drinking water and food, recontamination with
pathogens is believed to be prevented. In food, the
antibacterial activity of SCFA depends on the temperature
and moisture. Since minimal inhibitory concentration values
increase at increasing pH values, quite high concentrations
of SCFA are needed in the gut to achieve a direct
antimicrobial effect. The powder-form acids used as a feed
additive exert their effects in the upper GIT. When using
acids coated on a carrier or in encapsulated form, the acids
are thought to be protected from the intestinal environment
which allows the control of their site of action as well as the
velocity of release and dissociation(134). This is of
importance, as the main colonisation places for Salmonella
in chickens are the caeca(209). In epithelial cell lines and
primary chicken caecal epithelial cells, the invasion of
Salmonella typhimurium and S. enteritidis is suppressed
when the strains are pre-incubated in growth media
supplemented with various concentrations of butyrate,
while pre-incubation in acetate-supplemented medium
results in an increased invasion(210). The effect of SCFA
on Salmonella invasion is explained by changes in
expression patterns of genes of Salmonella pathogenicity
island (SPI)-1, which encodes for regulatory and effector
proteins and structural components of a needle complex,
necessary for invasion in epithelial cells. DNA microarrays
of both S. typhimurium and S. enteritidis grown in media
supplemented with low concentrations of butyrate show
specific down-regulation of SPI-1 while no alterations in
metabolic gene expression are seen when compared with
control samples(211). An opposite effect is observed in
enterohaemorrhagic Escherichia coli, a human pathogen
causing severe diarrhoea. Nakanishi et al. (212) showed that
butyrate enhances the expression of virulence-associated
genes in a concentration-dependent manner. Even at low
concentrations, butyrate triggers the adherence-related genes,
leading to efficient colonisation of the target niche(212).
Besides altering the pathogenicity of bacteria by
antimicrobial effects or by an effect on virulence gene
expression, butyrate has some effects on the host that can
significantly contribute to protection against pathogens. Via
in vivo experiments, it was shown that butyrate prevents
Clostridium perfringens-induced necrotic enteritis lesions in
broiler chickens(213). Because butyrate has no significant
antimicrobial effect against Clostridium perfringens, it can
be concluded that the observed results are due to effects of
butyrate on the host. A possible explanation could be a
faster replacement of epithelial cells in the necrotic foci by
the trophic effects of butyrate. Similar results can be
concluded for cell invasion assays using Campylobacter
jejuni. Butyrate-treated Caco2-cells were protected from
Campylobacter jejuni invasion in a concentration-depen-
dent manner(214). This effect was explained by the butyrate-
induced differentiation of the Caco-2 cells, as differentiated
monolayers cells are less susceptible to Campylobacter
jejuni invasion than undifferentiated cells(215).
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Concluding remarks and perspectives
The present paper underlines that butyrate is a natural
component of the biological liquids and tissues as well as of
digestive contents and that butyrate has particular properties
among the SCFA. It is produced in small quantities in
neonates, but its production greatly increases during the
development of the hindgut and/or forestomachs.
In omnivorous animals and in man, RS and fructo-
oligosaccharides are essential precursors for butyrate
production in the hindgut.
The present paper aims to highlight the biological role of
butyrate, whether it is naturally produced by the GI
microbial ecosystem or orally ingested as a feed additive.
Since in most circumstances butyrate seems to act in a
similar way when it is in the acid or salt form it appears that
only the radical [CH3-CH2-CH2-COO-] is of major
importance. Under physiological conditions, the increase
in performance could be explained, at least in part, by the
increased nutrient digestibility thanks to a delayed gastric
emptying and optimised pH of gastric digesta. This first
phase of digestion leads to a more efficient degradation of
dietary components in the gut, which are further processed
by pancreatic and intestinal enzymes stimulated by butyrate
entering the small intestine. Moreover, a decrease in
diarrhoea was observed perhaps in relation to modification
of ileal microbiota as well as that of large bowel content and
also to an improvement of epithelial integrity and defence
systems. The key consequences are beneficial systemic
effects on feed efficiency, growth rate and adiposity despite
the fact that butyrate remains undetectable in the peripheral
blood. Thus, butyrate could have an indirect effect on the
upper GIT or a direct effect on the lower GIT.
Numerous mechanisms are believed to contribute to the
beneficial effects of butyrate; however, many remain unclear.
In the digestive tract and in both situations (low and high doses
of butyrate in the lumen), butyrate is able to modify
development or rebuilding of the tissues. Thus, trophic effects
are on cell proliferation, resulting in a faster repair of necrotic
tissues. There is also an indirect way of butyrate action since this
molecule is not found in blood. This effect probably involves
substances produced by the hormono–neuro–immuno system.
Butyrate could also act on the intestinal microbiota
composition. Thus, the common mechanism of butyrate’s
indirect action on host GIT tissue cells and on micro-organisms
is at the molecular level, as butyrate was shown to operate at the
first stages of DNA damage in cell lines.
In animal production, studies showed that ingested
butyrate is a helpful feed additive as it allows pathogen
control, increases ration digestibility and growth rate, and
decreases oxidative stress and cytokine synthesis, even at
very low doses. The effects are predominantly noteworthy
in neonates and before weaning in piglets and calves.
We suggest that such effects could be developed to extend
the use of butyrate in the field of animal production and also
considered for new applications in human nutrition.
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